Literature DB >> 28916122

Myasthenia Gravis and Crisis: Evaluation and Management in the Emergency Department.

Jamie Roper1, M Emily Fleming1, Brit Long1, Alex Koyfman2.   

Abstract

BACKGROUND: Myasthenia gravis (MG) is an uncommon autoimmune disorder affecting the neuromuscular junction and manifesting as muscle weakness. A multitude of stressors can exacerbate MG. When symptoms are exacerbated, muscle weakness can be severe enough to result in respiratory failure, a condition known as myasthenic crisis (MC).
OBJECTIVE: This review discusses risk factors, diagnosis, management, and iatrogenic avoidance of MC. DISCUSSION: MC can affect any age, ethnicity, or sex and can be precipitated with any stressor, infection being the most common. MC is a clinical diagnosis defined by respiratory failure caused by exacerbation of MG. Muscle weakness can involve any voluntary muscle. MC can be differentiated from other neuromuscular junction diseases by the presence of normal reflexes, normal sensation, lack of autonomic symptoms, lack of fasciculations, and worsening weakness with repetitive motion. Treatment should target the inciting event and airway support. All acetylcholinesterase inhibitors should be avoided in crisis, including edrophonium testing and corticosteroids initially. Respiratory support can begin with noninvasive positive-pressure ventilation, as this has been successful even in patients with bulbar weakness. If intubation is necessary, consider avoiding paralytics or use a reduced dose of nondepolarizing agents.
CONCLUSIONS: MC should be in the differential of any patient with muscular weakness and respiratory compromise. Emergency department management of MC should focus on ruling out infection and respiratory support. Strong consideration should be given to beginning with noninvasive positive-pressure ventilation for ventilatory support. Corticosteroids, depolarizing paralytics, and acetylcholinesterase inhibitors should be avoided in patients with MC in the emergency department. Published by Elsevier Inc.

Entities:  

Keywords:  myasthenia gravis; myasthenic crisis; neurology; neuromuscular; respiratory; weakness

Mesh:

Year:  2017        PMID: 28916122     DOI: 10.1016/j.jemermed.2017.06.009

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  6 in total

Review 1.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

2.  Natural Autoimmunity to the Thyroid Hormone Monocarboxylate Transporters MCT8 and MCT10.

Authors:  Theresa Porst; Jörg Johannes; Hans Gluschke; Richard Köhler; Sebastian Mehl; Peter Kühnen; Kostja Renko; Waldemar B Minich; Susanna Wiegand; Lutz Schomburg
Journal:  Biomedicines       Date:  2021-04-30

Review 3.  Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay.

Authors:  Giuliana Galassi; Alessandro Marchioni
Journal:  Acta Neurol Belg       Date:  2021-04-02       Impact factor: 2.396

4.  Single-Breath Counting Test Predicts Non-Invasive Respiratory Support Requirements in Patients with COVID-19 Pneumonia.

Authors:  Yaroslava Longhitano; Christian Zanza; Tatsiana Romenskaya; Angela Saviano; Tonia Persiano; Mirco Leo; Andrea Piccioni; Marta Betti; Antonio Maconi; Ivano Pindinello; Riccardo Boverio; Jordi Rello; Francesco Franceschi; Fabrizio Racca
Journal:  J Clin Med       Date:  2021-12-29       Impact factor: 4.241

5.  Our Clinical Experience in the Treatment of Myasthenia Gravis Acute Exacerbations with a Novel Nanomembrane-Based Therapeutic Plasma Exchange Technology.

Authors:  Dimitar Tonev; Radostina Georgieva; Evgeniy Vavrek
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

6.  Atypical Initial Presentation of Painful Muscle Cramps in a Patient with Amyotrophic Lateral Sclerosis: A Case Report and Brief Review of the Literature.

Authors:  Aaron R Kuzel; Muhammad Uzair Lodhi; Intekhab Askari Syed; Mustafa Rahim
Journal:  Cureus       Date:  2017-11-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.